Table 1.
Characteristics of R and NR groups at baseline and at 12 weeks of treatment.
| CParameter | All patients (n = 60) | R group (n = 39) | NR group (n = 21) | P-value | ||||
|---|---|---|---|---|---|---|---|---|
| Gender (M/F) | 43/17 | 27/12 | 16/5 | 0.568 | ||||
| Age (years) | 38.95 ± 11.23 | 38.05 ± 11.25 | 40.62 ± 11.26 | 0.368 | ||||
| Baseline | ||||||||
| Total HBsAg, IU/ml | 198.78 ± 236.54 | 155.63 ± 194.33 | 287.35 ± 291.79 | 0.046 | ||||
| LHBs, ng/ml | 13.28 ± 1.89 | 12.49 ± 1.53 | 14.76 ± 1.59 | <0.001 | ||||
| MHBs, ng/ml | 7.19 ± 1.19 | 6.62 ± 0.88 | 8.23 ± 0.99 | <0.001 | ||||
| ALT, U/L | 31.31 ± 14.51 | 30.88 ± 14.62 | 33.17 ± 14.36 | 0.570 | ||||
| 12 weeks | ||||||||
| Total HBsAg, IU/ml | 91.93 ± 170.75 | 37.77 ± 57.15 | 189.92 ± 250.70 | 0.001 | ||||
| LHBs, ng/ml | 11.23 ± 2.10 | 10.22 ± 1.64 | 13.09 ± 1.52 | <0.001 | ||||
| MHBs, ng/ml | 6.20 ± 1.14 | 5.70 ± 0.90 | 7.12 ± 0.94 | <0.001 | ||||
| ALT, U/L | 76.78 ± 77.74 | 82.56 ± 89.52 | 66.05 ± 49.14 | 0.681 | ||||
| ALT>1.0×ULN | 53.33% (32/60) | 56.41%(22/39) | 47.62%(10/21) | 0.515 | ||||
| ALT>1.5×ULN | 41.67% (25/60) | 51.28% (20/39) | 23.81% (5/21) | 0.040 | ||||
| ALT>2.0×ULN | 23.33%(14/60) | 28.20%(11/39) | 14.29%(3/21) | 0.224 | ||||
| Change from baseline to 12 weeks | ||||||||
| Total HBsAg, log IU/ml | -0.73 ± 0.87 | -0.91 ± 0.96 | -0.38 ± 0.50 | 0.021 | ||||
| LHBs, log ng/ml | -0.08 ± 0.06 | -0.09 ± 0.07 | -0.05 ± 0.04 | 0.015 | ||||
| MHBs, log ng/ml | -0.07± 0.06 | -0.07 ± 0.07 | -0.06 ± 0.06 | 0.821 | ||||
HBsAg, Hepatitis B surface antigen; LHBs, large hepatitis B surface proteins; MHBs, middle hepatitis B surface proteins; ALT, alanine aminotransferase; ULN, upper limit of normal.